UPDATED: Sanofi and Regeneron pick up a blockbuster cardio approval–with a catch

Damian Garde

and won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped short of giving the treatment the wide label its makers wanted.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS